Brief: Arcutis Enrolls First Child In INTEGUMENT-INFANT Evaluating ZORYVE Cream 0.05% In Infants With Atopic Dermatitis
10/06/2025 13:58
June 10 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS ENROLLS FIRST CHILD IN INTEGUMENT-INFANT EVALUATING ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS Source text: ID:nGNXb4GXn7 Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4